黄芪注射液辅助治疗子宫内膜癌效果及其机制探析

Preliminary Study on Effect and Mechanism of Huangqi Injection(黄芪注射液)in Treatment of Endometrial Carcinoma

目的探究黄芪注射液辅助治疗在子宫内膜癌中的效果及其发挥作用的机制。方法将76名子宫内膜癌患者随机等分为对照组和观察组,对照组接受常规化疗,观察组在此基础上静脉注射黄芪注射液辅助治疗,观察两组患者的临床治疗效果、检测血清中人附睾蛋白4(HE4)、糖类抗原125(CA125)和转化生长因子β1(TGF-β1)的水平,及CD^(+)_(3)、CD^(+)_(4)和CD^(+)_(8) T细胞的百分比,并探究TGF-β1含量和临床病理特征关系。同时,体外细胞实验检测加入20%黄芪注射液后子宫内膜癌细胞株HEC-1-B的TGF-β1 mRNA及蛋白含量的变化,及其对细胞增殖和侵袭能力的影响;加入20%黄芪注射液的同时转染TGF-β1过表达质粒后,HEC-1-B细胞增殖和侵袭能力的变化。结果黄芪注射液辅助治疗的患者血清肿瘤标志物HE4和CA125含量和对照组比较显著降低(P<0.05),而外周血CD^(+)_(3)和CD^(+)_(4)/CD^(+)_(8)较对照组显著升高(P<0.05),同时,经黄芪注射液辅助治疗的患者相比于对照组患者临床治疗效果更好,客观缓解率和临床获益率均显著升高(P<0.05)。黄芪注射液辅助治疗的患者血清TGF-β1含量显著低于对照组,且TGF-β1含量与神经侵犯、病理分期和淋巴结转移有显著相关性(P<0.05)。体外细胞实验发现,黄芪注射液处理子宫内膜癌细胞HEC-1-B后,能够显著降低TGF-β1蛋白含量和mRNA表达水平,进而使细胞的增殖和侵袭能力显著下降;同时加入黄芪注射液并转染TGF-β1过表达质粒,发现TGF-β1蛋白含量和mRNA表达水平显著升高,并使细胞的增殖和侵袭能力显著增加。结论黄芪注射液辅助治疗子宫内膜癌临床治疗效果较好,且通过降低TGF-β1的表达来发挥效果。

Objective To explore the effect and mechanism of Huangqi Injection(黄芪注射液) in adjuvant therapy of endometrial carcinoma. Methods Seventy-six patients with endometrial carcinoma were randomly divided into control group and observation group. The control group received routine chemotherapy and the observation group on this basis received intravenous injection of Huangqi Injection. The clinical therapeutic effect, serum levels of human epididymal protein 4(HE4), carbohydrate antigen 125(CA125) and transforming growth factor β1(TGF-β1), and the percentages of CD^(+)_(3), CD^(+)_(4) and CD^(+)_(8)T cells in the two groups were observed. We also explored the relationship between the content of TGF-β1 and clinicopathological features. At the same time, the changes of TGF-β1 mRNA and protein content of endometrial cancer cell line HEC-1-B and its effect on cell proliferation and invasion were detected by cell experiment in vitro, and the changes of proliferation and invasion ability of HEC-1-B cells were detected after transfection of TGF-β1 over-expression plasmid with 20% Huangqi Injection. Results The levels of serum tumor markers HE4 and CA125 in the patients treated with Huangqi Injection were significantly lower than those in the control group, while the levels of CD^(+)_(3) and CD^(+)_(4)/CD^(+)_(8) in peripheral blood were significantly higher than those in the control group. At the same time, the clinical therapeutic effect of the patients treated with Huangqi Injection was better than that of the control group, and the objective remission rate and clinical benefit rate were significantly higher than those in the control group. The level of serum TGF-β1 in the patients treated with Huangqi Injection was significantly lower than that in the control group, and the content of TGF-β1 was significantly correlated with nerve invasion, pathological stage and lymph node metastasis. In vitro cell experiment showed that Huangqi Injection could significantly decrease the TGF-β1 protein content and mRNA expression level of endometrial cancer cell HEC-1-B, and then significantly lower the cell proliferation and invasion ability, while adding Huangqi Injection and transfecting TGF-β1 over-expression plasmid, it was found that TGF-β1 protein content and mRNA expression level were significantly increased, and the cell proliferation and invasion ability were significantly increased. Conclusion Huangqi Injection is effective in the adjuvant treatment of endometrial carcinoma, and it is effective by reducing the expression of TGF-β1.